Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis

✍ Scribed by Dirk Lossnitzer; Henning Steen; Alexandra Zahn; Stephanie Lehrke; Celine Weiss; Karl Heinz Weiss; Evangelos Giannitsis; Wolfgang Stremmel; Peter Sauer; Hugo A Katus; Daniel N Gotthardt

• Publisher: BioMed Central
• Year: 2010
• Tongue: English
• Weight: 955 KB
• Volume: 12
• Category: Article
• ISSN: 1097-6647
• DOI: 10.1186/1532-429x-12-47

✦ Synopsis

Abstract

Background

Portal hypertension and cardiac alterations previously described as "cirrhotic cardiomyopathy" are known complications of end stage liver disease (ELD). Cardiac failure contributes to morbidity and mortality, particularly after liver transplantation and transjugular intrahepatic portosystemic shunt (TIPS). We sought to identify myocardial tissue characterization and evaluate cardiovascular magnetic resonance (CMR) for diagnosis of cardiac impairment.

Results

Twenty ELD patients underwent CMR for morphological, functional and tissue characterization by late gadolinium enhancement (LGE). Based on extent of LGE, patients were dichotomized into high and low LGE groups and analyzed regarding liver, cardiocirculatory and renal functions. CMR demonstrated hyperdynamic left ventricular function and a patchy pattern of LGE of the myocardium to a variable extent (range 2-62%) in all patients. There were no significant differences in Model for End-Stage Liver Disease (MELD), Child-Pugh score or the left ventricular ejection fraction between high and low LGE groups. QTc-interval was prolonged in 25% of the patients. E/A ratio was at the upper limit of norm; no difference between groups. Patients showing high LGE had a higher CI (p < 0.05). Biomarkers of myocardial stress were elevated. While NT-proBNP and c-Troponin-T showed no differences, PLGF and sFLT1 were lower in the high LGE group.

Conclusion

CMR shows myocardial involvement in patients with ELD resembling appearance of myocarditis. The hyperdynamic circulation in portal hypertension may be an important factor. Larger prospective trials are warranted to confirm the association with severity and outcome of liver disease and to test the predictive power of CMR for patients listed for liver transplantation.